STOCK TITAN

Y-Mabs Therapeutics Inc - YMAB STOCK NEWS

Welcome to our dedicated news page for Y-Mabs Therapeutics (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Y-Mabs Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Y-Mabs Therapeutics's position in the market.

Rhea-AI Summary
Y-mAbs Therapeutics, Inc. announces the resignation of Chief Financial Officer, Bo Kruse, and the commencement of a search process for a successor. The company expresses gratitude for Kruse's contributions and commitment over the years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
management
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. appoints Dr. Mary Tagliaferri, a seasoned biopharmaceutical expert, to its Board of Directors. Dr. Tagliaferri brings extensive industry experience and oncology therapeutic development expertise to the company. Her addition is expected to bolster Y-mAbs' advancement in developing novel cancer therapies using the Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
management
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. reported strong financial results for Q4 and FY 2023 with record DANYELZA net product revenues of $23.4 million and $84.3 million, representing YoY growth of 42% and 71% respectively. The company has cash and cash equivalents of $78.6 million as of December 31, 2023, supporting operations into 2027. Y-mAbs also announced full year 2024 financial guidance, anticipating net product revenues of $95-100 million and operating expenses of $115-120 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.92%
Tags
earnings
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. (YMAB) will release its financial results for Q4 and FY 2023 on February 29, 2024, followed by a conference call on March 1, 2024. Key executives will participate in the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
earnings
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. (YMAB) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
conferences
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. (YMAB) will be added to the NASDAQ Biotechnology Index (NBI) on December 18, 2023. The index tracks the performance of biotech and pharmaceutical companies listed on NASDAQ, and companies must meet specific eligibility requirements to be included.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Rhea-AI Summary
YMAB - Y-mAbs Therapeutics, Inc. reports Q3 2023 DANYELZA net product revenues of $20.0 million, a 59% YoY growth. FDA clearance for CD38-SADA for non-Hodgkin Lymphoma. Cash and cash equivalents of $86.6 million as of September 30, 2023, extending cash runway into 2027. Management updates FY 2023 financial guidance by lowering anticipated operating expenses and use of cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.84%
Tags
earnings
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. will report its financial results for Q3 2023 on November 13, 2023. The announcement will be followed by a conference call and webcast on November 14, 2023. Participants include the President, CEO, CFO, and other key executives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
earnings
-
Rhea-AI Summary
Y-mAbs Therapeutics appoints Michael Rossi as President and CEO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
none
Rhea-AI Summary
Y-mAbs Therapeutics announces FDA clearance of IND application for CD38-SADA program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
clinical trial
Y-Mabs Therapeutics Inc

Nasdaq:YMAB

YMAB Rankings

YMAB Stock Data

722.32M
27.56M
14.55%
61.88%
4.97%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About YMAB

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.